The Metabolic Health Crisis Is Not a Supplement Deficiency

America's Metabolic Health Problem Is Real

The Centers for Disease Control and Prevention estimates that 40.1 million Americans have diabetes. Another 115.2 million adults have prediabetes, representing more than two in five American adults, and most people with prediabetes do not know they have it.

Another statistic appears frequently in discussions of metabolic health: roughly 88% of American adults are said to be metabolically unhealthy. That figure comes from a 2019 analysis of National Health and Nutrition Examination Survey data collected between 2009 and 2016. Researchers used a demanding definition of optimal metabolic health. Participants had to meet favorable criteria for waist circumference, fasting glucose and hemoglobin A1c, blood pressure, triglycerides and HDL cholesterol without taking medication for those conditions. Only 12.2% met every criterion.

Saying that 87.8% of American adults therefore had diabetes or a diagnosed metabolic disease goes beyond what the study showed. They failed to meet at least one criterion in a strict definition of optimal metabolic health.

A later analysis using a broader cardiometabolic definition was hardly reassuring. Using NHANES data through 2017–2018, researchers found that only 6.8% of American adults met optimal levels across adiposity, glucose, blood lipids, blood pressure and absence of clinical cardiovascular disease.

The estimates change depending on how metabolic health is defined, but every reasonable definition points toward a large population-level problem involving glucose regulation, obesity, blood pressure, lipids and cardiovascular risk.

Blood Sugar Is an Outcome. It Is Also a Treatment Target.

A popular explanation of insulin resistance argues that elevated glucose is merely a downstream result and that treating blood sugar therefore misses the underlying problem. There is useful physiology behind the first part of that argument. Fasting glucose can remain normal for years while the pancreas produces progressively more insulin to compensate for worsening insulin resistance. By the time fasting glucose or A1c rises substantially, metabolic dysfunction may already have been developing for some time.

The conclusion that glucose itself is therefore unimportant does not follow. Chronic hyperglycemia contributes directly to the microvascular complications of diabetes involving the retina, kidneys and peripheral nerves. Glycemic targets remain central to evidence-based diabetes care because prolonged glucose exposure has consequences of its own.

Good metabolic medicine looks upstream without ignoring what is happening downstream. Someone with rising glucose may need evaluation of body composition, visceral adiposity, physical activity, diet, sleep, medications and other contributors to insulin resistance. When hyperglycemia is already present, it deserves treatment as well.

What Actually Drives Insulin Resistance?

Insulin resistance does not arise because one biochemical switch becomes defective after a nutrient goes missing. Skeletal muscle, liver and adipose tissue all participate in glucose and energy metabolism, and dysfunction can develop differently in each tissue.

In skeletal muscle, physical inactivity and impaired metabolic flexibility can reduce glucose disposal. In the liver, insulin resistance can allow excessive glucose production even when circulating insulin is already elevated. In adipose tissue, particularly when normal fat-storage capacity is exceeded, greater fatty-acid flux and abnormal signaling can contribute to insulin resistance elsewhere in the body.

The surrounding clinical environment also matters. Genetics influence susceptibility. Aging changes body composition and metabolic reserve. Menopause can alter fat distribution. Certain medications can worsen glucose regulation. Sleep apnea and chronically insufficient sleep are associated with poorer metabolic health. Chronic stress can influence appetite, sleep and activity. Food availability, neighborhood design, work schedules, socioeconomic circumstances and the modern food environment shape behavior long before anyone considers an insulin-sensitizing supplement.

Inflammation and oxidative stress often appear within insulin-resistant states, but they are part of this larger physiology rather than isolated abnormalities waiting to be corrected by an antioxidant formula. A useful treatment strategy starts by asking what is actually abnormal in the individual patient.

Muscle Is Part of Glucose Regulation

Skeletal muscle is a major destination for glucose after a meal. Muscle contraction can increase glucose uptake through pathways that are not entirely dependent on insulin, while regular physical activity improves insulin responsiveness over time.

Muscle health and metabolic health belong in the same clinical conversation. Exercise is therefore poorly described when it is discussed only as a way to burn calories.

Aerobic exercise improves cardiorespiratory fitness and glucose regulation. Resistance training helps preserve or increase strength and lean tissue. Current American Diabetes Association guidance recommends resistance exercise two to three times each week for adults with diabetes in addition to regular aerobic activity.

Muscle preservation becomes especially important during substantial weight loss. The 2026 ADA Standards specifically emphasize muscle-strengthening exercise for people using obesity pharmacotherapy or undergoing metabolic surgery because of its potential role in maintaining lean body mass.

For a broader discussion of the relationship between muscle and healthy aging, see Muscle Matters. But Longevity Is Bigger Than Muscle.

Visceral Fat and Ectopic Fat Change the Metabolic Environment

Body weight is an imperfect metabolic measurement because it says very little about where fat is stored or how much lean tissue a person carries.

Visceral fat surrounds the organs within the abdomen and is more strongly associated with insulin resistance and cardiometabolic risk than subcutaneous fat stored beneath the skin. Fat accumulation in organs such as the liver can also interfere with normal metabolism, including in people who do not appear markedly obese.

This helps explain why two people with the same BMI can have very different metabolic profiles and why improvement in glucose regulation can occur after meaningful fat loss even before someone reaches a theoretically ideal body weight.

The Diabetes Prevention Program provides one of the clearest examples. In people at high risk of developing type 2 diabetes, the lifestyle program targeted approximately 7% weight loss and at least 150 minutes of moderate physical activity each week. Participants who achieved the physical-activity goal without reaching the weight-loss goal still experienced a substantial reduction in diabetes incidence.

Current ADA guidance continues to recommend approximately 5–7% weight loss for many adults with overweight or obesity who are at high risk for type 2 diabetes, together with regular physical activity and an evidence-based dietary pattern.

At HormoneSynergy®, DEXA and SECA body-composition testing may be used when knowing the amount and distribution of fat and lean tissue can change the clinical strategy.

See Body Composition and Longevity Medicine.

Sleep Is Metabolic Care

Sleep is still sometimes presented as general wellness advice added after the more serious metabolic discussion has ended. Current evidence makes that separation increasingly difficult to defend.

Sleep duration, sleep quality and circadian timing influence glucose regulation, appetite, sympathetic activity and endocrine function. Obstructive sleep apnea deserves particular attention because it commonly accompanies obesity and insulin resistance and can remain undiagnosed for years.

The ADA now places sleep alongside nutrition and physical activity within the behavioral foundations of diabetes prevention and treatment. Someone sleeping five fragmented hours a night with untreated obstructive sleep apnea needs assessment of the sleep disorder, not simply another ingredient marketed for insulin sensitivity.

Where Supplements Actually Fit

A supplement-centered approach to metabolic disease is not supported by the evidence, but rejecting that model does not require pretending supplements never have clinical value.

Deficiency provides the clearest example. Magnesium deficiency should be corrected when it is present. People taking metformin may require monitoring for vitamin B12 deficiency. Restrictive diets, gastrointestinal disease, medications and other medical circumstances can create legitimate nutritional needs.

Some compounds also have pharmacologic effects despite being sold as supplements. Berberine is a good example. Randomized trials and meta-analyses suggest effects on fasting glucose, post-meal glucose and other metabolic measurements. Those findings justify clinical interest in berberine; they do not redefine insulin resistance as a berberine deficiency.

The American Diabetes Association does not recommend routine supplementation with magnesium, chromium, herbs or spices for glycemic benefit in people with diabetes. This does not mean every study of these compounds is negative. It means the total evidence has not established them as reliable substitutes for interventions with stronger and more consistent effects on metabolic outcomes.

Targeted supplementation makes the most sense when there is a documented deficiency, a specific physiological rationale or sufficient clinical evidence to justify an adjunctive role.

What About Popular Insulin-Sensitivity Ingredients?

Berberine and Dihydroberberine

Berberine has considerably more human clinical research than many supplements marketed for metabolic health. A 2024 systematic review of randomized trials found reductions in fasting glucose, post-meal glucose and several lipid measures, with additional improvement in HbA1c when berberine was combined with glucose-lowering medication.

The literature is not uniform. Study quality, formulation, dose, population and background treatment vary considerably, which limits how confidently results from one trial can be generalized to another patient or product.

Dihydroberberine is a metabolite of berberine marketed partly on the basis of greater oral bioavailability. Pharmacokinetic evidence is interesting, but greater delivery of a molecule does not establish better long-term clinical outcomes. Claims about HbA1c, prevention of diabetes or cardiovascular outcomes require direct clinical evidence for the formulation making those claims.

Alpha-Lipoic Acid

Alpha-lipoic acid has antioxidant and metabolic effects and has been studied in people with diabetes. Meta-analyses have reported modest improvements in some glycemic markers, including fasting glucose and HbA1c.

The magnitude of those effects deserves attention. In one dose-response meta-analysis, the estimated reduction in HbA1c was modest, and the investigators noted that changes in several outcomes remained below commonly used thresholds for clinical importance.

Alpha-lipoic acid may still have a role in selected circumstances, including its better-established history in diabetic neuropathy research, without being positioned as a primary treatment for insulin resistance.

Magnesium

Magnesium participates in hundreds of enzymatic reactions and contributes to normal insulin signaling. Inadequate magnesium intake is common enough to deserve clinical attention, particularly when diet, medications or gastrointestinal disease create a plausible deficiency.

Physiological importance, however, does not automatically justify universal supplementation. A 2026 systematic review and meta-analysis of 15 randomized trials involving people with diabetes or prediabetes found no statistically significant overall improvement in insulin or HOMA-IR with oral magnesium supplementation. Response may vary according to baseline status, and correcting genuine deficiency remains appropriate.

Chromium

Chromium has been marketed for glucose metabolism for decades. Individual studies and meta-analyses have produced mixed results, with substantial differences among populations, formulations, doses and trial designs. Current ADA guidance does not recommend chromium supplementation for glycemic benefit.

Curcumin and Other Antioxidant Strategies

Curcumin and related compounds have biological effects relevant to inflammatory and oxidative pathways, and clinical research continues to examine those effects. Metabolic disease, however, cannot be reduced to an antioxidant deficit.

Reducing a marker of oxidative stress does not necessarily translate into prevention of diabetes, cardiovascular disease or the complications of chronic hyperglycemia. Current diabetes guidelines do not recommend routine curcumin or herbal supplementation for glycemic management.

What Has the Strongest Evidence?

The interventions with the deepest evidence base are also among the least exotic. Physical activity improves insulin sensitivity and cardiovascular fitness. Resistance training improves muscle function and contributes to glucose disposal. Dietary patterns centered on minimally processed foods can improve energy balance and cardiometabolic risk. Meaningful reduction of excess body fat can substantially improve glucose regulation in people with overweight or obesity.

Sleep disorders deserve treatment. Smoking deserves attention. Blood pressure and atherogenic lipoproteins should not be ignored simply because the conversation began with insulin resistance, since cardiovascular disease remains central to the long-term risk carried by diabetes and metabolic dysfunction.

When lifestyle treatment is not enough, medication is not evidence of failure. Metformin remains useful in appropriately selected patients. GLP-1 and GIP/GLP-1 therapies can produce substantial improvements in weight and metabolic health in selected people. Other diabetes medications are chosen according to glucose control, cardiovascular disease, kidney disease, heart failure and the individual clinical situation. Metabolic surgery remains one of the most effective treatments for severe obesity and can produce profound metabolic improvement.

These treatments do not all work through the same biological pathway, nor do they need to. Their value comes from clinical evidence showing that they can meaningfully change metabolic health and, for several therapies, important cardiovascular or kidney outcomes.

Fasting Glucose Is Useful, but It Is Not the Whole Metabolic Evaluation

Fasting glucose can remain normal while insulin resistance is developing. Hemoglobin A1c adds information about longer-term glycemia, while triglycerides, HDL cholesterol, waist circumference, blood pressure and body composition provide additional information about the metabolic environment.

Fasting insulin and HOMA-IR can sometimes add context, particularly when the clinical picture suggests insulin resistance before glucose becomes clearly abnormal. They are not universally standardized diagnostic tests, and no HOMA-IR value should be interpreted in isolation from the rest of the clinical picture.

Continuous glucose monitoring can reveal patterns in post-meal glucose and daily glucose variability that a fasting measurement cannot show. Those excursions still need context. A graph generated by a sensor is information; it is not automatically a diagnosis.

For a deeper discussion, see What Blood Tests Detect Insulin Resistance? and HOMA-IR and Insulin Resistance.

Putting Metabolic Health Back in Context

America's metabolic health problem is large enough to create an equally large market for products promising to improve insulin sensitivity, mitochondrial function, inflammation, oxidative stress or glucose metabolism. Some of those products contain biologically active compounds, and some have worthwhile human clinical evidence. Used selectively, they can have a place in medical care.

They do not explain why more than 115 million American adults have prediabetes.

Insulin resistance develops through the interaction of adipose tissue, skeletal muscle, liver physiology, diet, physical activity, sleep, genetics, medications, hormones and the surrounding environment. Once glucose begins to rise, the underlying physiology and the hyperglycemia both deserve attention.

The clinical task is therefore not to assemble the longest list of insulin-sensitizing ingredients. It is to determine what is driving metabolic dysfunction in an individual patient and choose interventions capable of changing it.

A supplement may belong in that plan. It should not be mistaken for the plan itself.

Frequently Asked Questions

What is metabolic health?

Metabolic health generally refers to favorable regulation of glucose, blood pressure, blood lipids, body-fat distribution and related cardiometabolic risk factors. Definitions vary between studies, which is one reason estimates of how many Americans are metabolically healthy also vary.

Is it true that 88% of Americans are metabolically unhealthy?

A widely cited NHANES analysis found that 12.2% of American adults met every criterion in a strict definition of optimal metabolic health. The remaining 87.8% failed to meet at least one criterion. That is not the same as saying that all of them had diabetes or another diagnosed metabolic disease.

How many Americans have prediabetes?

CDC's 2026 National Diabetes Statistics Report estimates that 115.2 million American adults have prediabetes. The CDC also estimates that 40.1 million Americans have diabetes.

Can insulin resistance occur with normal fasting glucose?

Yes. The pancreas can compensate for insulin resistance by producing more insulin, allowing fasting glucose to remain in the normal range for a period of time. Fasting glucose is therefore useful but does not describe every aspect of insulin sensitivity.

Is blood sugar only a symptom of insulin resistance?

No. Rising glucose can result from insulin resistance and beta-cell dysfunction, but chronic hyperglycemia also contributes directly to diabetes complications. Clinical care addresses both the physiology producing dysglycemia and the glucose itself.

What is the best supplement for insulin resistance?

No supplement has been established as a universal treatment for insulin resistance. Some compounds, including berberine and alpha-lipoic acid, have human clinical evidence, while others have inconsistent or limited data. Treatment should begin with the metabolic drivers present in the individual.

Does magnesium improve insulin resistance?

Magnesium is physiologically important, and deficiency should be corrected when present. A 2026 meta-analysis of randomized trials in people with diabetes and prediabetes did not find a statistically significant overall improvement in insulin or HOMA-IR from magnesium supplementation.

Does berberine lower blood sugar?

Randomized trials and meta-analyses suggest that berberine can reduce fasting and post-meal glucose and may improve several other metabolic markers. Study quality and treatment protocols vary, and berberine should not be considered a replacement for established diabetes or obesity treatment.

Does exercise improve insulin sensitivity?

Yes. Aerobic activity and resistance training improve aspects of glucose metabolism and are recommended in current diabetes prevention and treatment guidelines. Muscle-strengthening exercise becomes particularly relevant when substantial weight loss creates a risk of losing lean mass.

Can prediabetes be reversed?

Glucose measurements can return to the normal range in some people with prediabetes, particularly after meaningful improvements in weight, physical activity, diet and other metabolic factors. Continued monitoring remains appropriate because future metabolic risk may persist.

Related HormoneSynergy® Reading

• Metabolic Health and Longevity Medicine
• Insulin Resistance Explained
• What Blood Tests Detect Insulin Resistance?
• HOMA-IR and Insulin Resistance
• Body Composition and Longevity Medicine
• Best Diet for Insulin Resistance and Visceral Fat
• Muscle Matters. But Longevity Is Bigger Than Muscle.

Selected Research

• Centers for Disease Control and Prevention. National Diabetes Statistics Report. Updated 2026.
• Araújo J, Cai J, Stevens J. Prevalence of Optimal Metabolic Health in American Adults: National Health and Nutrition Examination Survey 2009–2016. Metab Syndr Relat Disord. 2019;17(1):46-52. PMID: 30484738.
• O'Hearn M, et al. Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999–2018. J Am Coll Cardiol. 2022;80(2):138-151. PMID: 35798448.
• American Diabetes Association Professional Practice Committee. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
• American Diabetes Association Professional Practice Committee. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
• American Diabetes Association Professional Practice Committee. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
• Wang J, et al. Effects of administering berberine alone or in combination on type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1455534. PMID: 39640489.
• Jibril AT, Jayedi A, Shab-Bidar S. Efficacy and safety of oral alpha-lipoic acid supplementation for type 2 diabetes management: a systematic review and dose-response meta-analysis of randomized trials. Endocr Connect. 2022;11:e220322. PMID: 36006850.
• Amiri A, et al. Oral magnesium supplements and insulin resistance in individuals with diabetes and pre-diabetes: an updated systematic review and meta-analysis of randomized controlled trials. BMC Nutr. 2026. PMID: 42426860.

Important Notice: This article is educational and is not a substitute for individualized medical care. Diabetes and prediabetes require appropriate medical evaluation. Supplements can interact with prescription medications and may affect glucose levels, blood pressure, bleeding risk and other aspects of health.